Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03953326 · ClinicalTrials.gov registry record · Phase 1
HeartPhone Cancer Survivors Trial 2019
A Phase 1 study, sponsored by Penn State University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT03953326: Clinical Trial Phase 1 study, sponsored by Penn State University.
NCT03953326 is a Phase 1 study that was terminated before completion, run by Penn State University. The registered enrollment target is 2 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03953326, a Phase 1 study, was terminated before completion, sponsored by Penn State University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a behavioral study that will examine changes in physical activity and vascular health in response to a digital tool (app) that will appear on participant's lock screen of their Android phone. Participants will be asked to use this app for 3 months and to wear a Fitbit device continuously throughout the study. Participants will be asked to complete questionnaires, participate in fitness testing and measures of cardiovascular health at 3 months and 6 months after baseline assessments. The hypothesis is that exposure to the app will lead to increased physical activity volume and improved microvessel function.
Primary Outcome
Change in the total physical activity volume from baseline to 3 months as measured by the Actigraph GT3XP-BTLE (total activity counts)
Interventions
- DRUG Acetylcholine
- DRUG Sodium Nitroprusside
- BEHAVIORAL HeartPhone app
- DRUG L-Arginine, N2-((4-Methylphenyl)Sulfonyl)-, Methyl Ester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-04-23 |
| Est. Completion | 2020-12-31 |
| Phase | Phase 1 |
Why NCT03953326 stopped before completion
NCT03953326 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 4 interventions - of which Acetylcholine is the first listed.
NCT03953326 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03953326 about?
NCT03953326 is a clinical study titled "HeartPhone Cancer Survivors Trial 2019". This is a behavioral study that will examine changes in physical activity and vascular health in response to a digital tool (app) that will appear on participant's lock screen of their Android phone. Participants will be asked to use this app for 3 months and to wear a Fitbit device continuously thr...
What is the current status of trial NCT03953326?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2019-04-23. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT03953326?
The interventions under investigation include: Acetylcholine (DRUG), Sodium Nitroprusside (DRUG), HeartPhone app (BEHAVIORAL), L-Arginine, N2-((4-Methylphenyl)Sulfonyl)-, Methyl Ester (DRUG).
Who is sponsoring clinical trial NCT03953326?
This trial is sponsored by Penn State University, which has 219 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03953326's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI